Targeting KRAS-driven NSCLC

Jia Luo, MD, Dana-Farber Cancer Institute, Boston, MA, discusses targeting KRAS mutations in non-small cell lung cancer (NSCLC), which has historically been an unfeasible endeavor despite their prevalence as oncogenic drivers. Now, there are multiple KRAS-targeted drugs being explored in early phase clinical trials for the treatment of KRAS-driven NSCLC. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.